Small Caps Dashboard
 

PARAGON CARE


Sector: Medical technology

Industry:

WHY WE ARE WATCHING

The almost halving of the share price over the past nine months of this medical supply business gave us an opportunity to look at the company. Healthcare services are close to essential, have a high level of government funding, with long-term growth supported by an increasing and aging population. The company is in the early stages of a turnaround and we are looking at whether management can deliver on its own high expectations.

WHAT'S NEW?

Paragon’s 1H19 result was disappointing as costs from a spate of acquisitions were greater than expected, leading to a loss. Although revenues more than doubled to $130m the business made EBITDA of only $9.5m, leading to a loss after tax of $4.2m, down $7m on a year ago. A silver lining of sorts was the continuing business (excluding businesses for sale), which achieved 9% organic revenue growth and the gross margin was stable at 38% ($119m revenue and $14m EBITDA). The interim dividend was held at 1.1 cents.

**FY19 Forecast

See our recomndations.
Unlock

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec porttitor semper molestie. Ut eleifend, erat eu pulvinar iaculis, odio nunc venenatis tellus, ut placerat lorem purus sed tellus. Duis ut leo vitae massa facilisis dictum sed a dui. Proin quis pulvinar purus, vestibulum lobortis justo.

 
  • Radar Rating Unlock
  • Market Cap ($m)* 77.7
  • Dividend Yield (%)* 0
  • NET DEBT ($M) 76.3
  • * Data as of 18 November 2021

Latest Research Summary

PARAGON CARE: RESEARCH TIP - MAY 2019
01 May, 2019

Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Maecenas ut ex et est semper fringilla. Nam et lectus augue. Integer non consectetur ligula. Maecenas tortor metus, molestie at aliquam sit amet, feugiat sed ipsum. Donec vehicula mi ac neque tempor dignissim.

Unlock to view the latest research

Previous Research

Research Date Radar Rating  
PARAGON CARE: RESEARCH TIP - MAY 2019 01 May, 2019 8a5e9ca1 View Research